ARGX Fundamental Analysis - ARGENX SE

Fundamental Rating

Overall ARGX gets a fundamental rating of 6 out of 10. We evaluated ARGX against 83 industry peers in the Biotechnology industry. While ARGX has a great health rating, its profitability is only average at the moment. ARGX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes ARGX very considerable for growth investing!

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ARGX was profitable.
ARGX had a positive operating cash flow in the past year.
In the past 5 years ARGX reported 4 times negative net income.
In the past 5 years ARGX always reported negative operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of 17.84%, ARGX belongs to the best of the industry, outperforming 91.57% of the companies in the same industry.
The Return On Equity of ARGX (21.00%) is better than 90.36% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.71%, ARGX belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	17.84%
ROE	21%
ROIC	5.71%

ROA(3y)-5.23%

ROA(5y)-11.34%

ROE(3y)-5.76%

ROE(5y)-13.95%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 41.97%, ARGX belongs to the top of the industry, outperforming 95.18% of the companies in the same industry.
With an excellent Operating Margin value of 15.30%, ARGX belongs to the best of the industry, outperforming 83.13% of the companies in the same industry.
Looking at the Gross Margin, with a value of 89.40%, ARGX belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.

		Industry Rank	Sector Rank
OM	15.3%
PM (TTM)	41.97%
GM	89.4%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ARGX is destroying value.
The number of shares outstanding for ARGX has been increased compared to 1 year ago.
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
The debt/assets ratio for ARGX is higher compared to a year ago.

2.2 Solvency

ARGX has an Altman-Z score of 29.21. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 29.21, ARGX belongs to the best of the industry, outperforming 95.18% of the companies in the same industry.
The Debt to FCF ratio of ARGX is 0.14, which is an excellent value as it means it would take ARGX, only 0.14 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ARGX (0.14) is better than 92.77% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.01, ARGX belongs to the best of the industry, outperforming 85.54% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	0.14
Altman-Z	29.21

ROIC/WACC0.77

WACC7.43%

2.3 Liquidity

A Current Ratio of 5.60 indicates that ARGX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 5.60, ARGX belongs to the best of the industry, outperforming 83.13% of the companies in the same industry.
A Quick Ratio of 5.27 indicates that ARGX has no problem at all paying its short term obligations.
The Quick ratio of ARGX (5.27) is better than 84.34% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.6
Quick Ratio	5.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1512.50% over the past year.
Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 64.71%.
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.

EPS 1Y (TTM)1512.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%272.66%

Revenue 1Y (TTM)64.71%

Revenue growth 3Y63.92%

Revenue growth 5Y94.61%

Sales Q2Q%95.51%

3.2 Future

ARGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 105.80% yearly.
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 35.42% on average per year.

EPS Next Y935.48%

EPS Next 2Y313.05%

EPS Next 3Y178.04%

EPS Next 5Y105.8%

Revenue Next Year95.19%

Revenue Next 2Y63.47%

Revenue Next 3Y48.27%

Revenue Next 5Y35.42%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 64.74, ARGX can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of ARGX indicates a somewhat cheap valuation: ARGX is cheaper than 77.11% of the companies listed in the same industry.
ARGX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.30.
With a Price/Forward Earnings ratio of 27.28, ARGX can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ARGX is valued cheaply inside the industry as 80.72% of the companies are valued more expensively.
ARGX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.04.

		Industry Rank	Sector Rank
PE	64.74
Fwd PE	27.28

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ARGX is valued a bit cheaper than 74.70% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 80.72% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	160.56
EV/EBITDA	90.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 178.04% in the coming years.

PEG (NY)0.07

PEG (5Y)N/A

EPS Next 2Y313.05%

EPS Next 3Y178.04%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ARGX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARGENX SE

EBR:ARGX (1/14/2026, 5:36:15 PM)

690.8

-6.2 (-0.89%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-30 2025-10-30/bmo

Earnings (Next)01-12 2026-01-12/amc

Inst Owners43.42%

Inst Owner ChangeN/A

Ins Owners0.12%

Ins Owner ChangeN/A

Market Cap42.53B

Revenue(TTM)3.60B

Net Income(TTM)1.28B

Analysts84

Price Target837.1 (21.18%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)15.16%

Min EPS beat(2)7.11%

Max EPS beat(2)23.2%

EPS beat(4)3

Avg EPS beat(4)3962.36%

Min EPS beat(4)-38.07%

Max EPS beat(4)15857.2%

EPS beat(8)5

Avg EPS beat(8)1996.71%

EPS beat(12)8

Avg EPS beat(12)1343.38%

EPS beat(16)12

Avg EPS beat(16)1012.62%

Revenue beat(2)1

Avg Revenue beat(2)3.68%

Min Revenue beat(2)-0.81%

Max Revenue beat(2)8.17%

Revenue beat(4)3

Avg Revenue beat(4)5.02%

Min Revenue beat(4)-0.81%

Max Revenue beat(4)8.17%

Revenue beat(8)6

Avg Revenue beat(8)5.96%

Revenue beat(12)10

Avg Revenue beat(12)14%

Revenue beat(16)13

Avg Revenue beat(16)17.53%

PT rev (1m)-1.06%

PT rev (3m)13.84%

EPS NQ rev (1m)-0.95%

EPS NQ rev (3m)0.11%

EPS NY rev (1m)-0.42%

EPS NY rev (3m)14.37%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0.56%

Revenue NY rev (1m)0.12%

Revenue NY rev (3m)5.34%

Valuation

		Industry Rank	Sector Rank
PE	64.74
Fwd PE	27.28
P/S	16.25
P/FCF	160.56
P/OCF	122.76
P/B	8.13
P/tB	8.43
EV/EBITDA	90.6

EPS(TTM)10.67

EY1.54%

EPS(NY)25.33

Fwd EY3.67%

FCF(TTM)4.3

FCFY0.62%

OCF(TTM)5.63

OCFY0.81%

SpS42.52

BVpS84.96

TBVpS81.9

PEG (NY)0.07

PEG (5Y)N/A

Graham Number142.81

Profitability

		Industry Rank	Sector Rank
ROA	17.84%
ROE	21%
ROCE	7.61%
ROIC	5.71%
ROICexc	15.87%
ROICexgc	17.62%
OM	15.3%
PM (TTM)	41.97%
GM	89.4%
FCFM	10.12%

ROA(3y)-5.23%

ROA(5y)-11.34%

ROE(3y)-5.76%

ROE(5y)-13.95%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.43

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	0.14
Debt/EBITDA	0.07
Cap/Depr	428.74%
Cap/Sales	3.12%
Interest Coverage	519.07
Cash Conversion	82.6%
Profit Quality	24.11%
Current Ratio	5.6
Quick Ratio	5.27
Altman-Z	29.21

F-Score6

WACC7.43%

ROIC/WACC0.77

Cap/Depr(3y)176.19%

Cap/Depr(5y)545.91%

Cap/Sales(3y)10.66%

Cap/Sales(5y)13.77%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)1512.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%272.66%

EPS Next Y935.48%

EPS Next 2Y313.05%

EPS Next 3Y178.04%

EPS Next 5Y105.8%

Revenue 1Y (TTM)64.71%

Revenue growth 3Y63.92%

Revenue growth 5Y94.61%

Sales Q2Q%95.51%

Revenue Next Year95.19%

Revenue Next 2Y63.47%

Revenue Next 3Y48.27%

Revenue Next 5Y35.42%

EBIT growth 1Y208.18%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year1529.77%

EBIT Next 3Y219.36%

EBIT Next 5Y122.96%

FCF growth 1Y140.74%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y161.76%

OCF growth 3YN/A

OCF growth 5YN/A

ARGENX SE / ARGX.BR FAQ

What is the fundamental rating for ARGX stock?

ChartMill assigns a fundamental rating of 6 / 10 to ARGX.BR.

What is the valuation status for ARGX stock?

ChartMill assigns a valuation rating of 5 / 10 to ARGENX SE (ARGX.BR). This can be considered as Fairly Valued.

Can you provide the profitability details for ARGENX SE?

ARGENX SE (ARGX.BR) has a profitability rating of 5 / 10.

What are the PE and PB ratios of ARGENX SE (ARGX.BR) stock?

The Price/Earnings (PE) ratio for ARGENX SE (ARGX.BR) is 64.74 and the Price/Book (PB) ratio is 8.13.

What is the earnings growth outlook for ARGENX SE?

The Earnings per Share (EPS) of ARGENX SE (ARGX.BR) is expected to grow by 935.48% in the next year.

ARGENX SE (ARGX.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ARGENX SE / ARGX.BR FAQ

What is the fundamental rating for ARGX stock?

What is the valuation status for ARGX stock?

Can you provide the profitability details for ARGENX SE?

What are the PE and PB ratios of ARGENX SE (ARGX.BR) stock?

What is the earnings growth outlook for ARGENX SE?